Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–86.

Article  CAS  PubMed  Google Scholar 

El Chaer F, Keng M, Ballen KK. MLL-Rearranged acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2020;15(2):83–9.

Article  PubMed  Google Scholar 

Künz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D, Steiner N. Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers (Basel). 2022;14(17).

Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol. 2012;24(2):182–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, et al. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study. Blood Adv. 2024;8(5):1155–66.

Article  PubMed  Google Scholar 

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 Evidence-Based review from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25(11):2113–23.

Article  PubMed  Google Scholar 

Pierce E, Mautner B, Mort J, Blewett A, Morris A, Keng M, et al. MRD in ALL: optimization and innovations. Curr Hematol Malig Rep. 2022;17(4):69–81.

Article  PubMed  Google Scholar 

Gökbuget N, Steffen B. How I treat older patients with Ph/BCR-ABL–negative acute lymphoblastic leukemia. Blood. 2025;145(1):53–63.

Article  PubMed  Google Scholar 

Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–62.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Jain N, Litzow MR, Luger SM, Papayannidis C, Ribera J-M, et al. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer. 2025;131(10):e35872.

Article  CAS  PubMed  Google Scholar 

Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, et al. Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn. 2009;11(3):201–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022;6(13):4006–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107(12):2783–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Fu H, Lai X, Tan Y, Zheng W, Shi J, et al. Minimal residual disease at first achievement of complete remission predicts outcome in adult patients with Philadelphia Chromosome-Negative acute lymphoblastic leukemia. PLoS ONE. 2016;11(10):e0163599.

Article  PubMed  PubMed Central  Google Scholar 

Bassan R, Brüggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028–39.

Article  PubMed  PubMed Central  Google Scholar 

Ribera J-M, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, et al. Treatment of High-Risk Philadelphia Chromosome–Negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–604.

Article  CAS  PubMed  Google Scholar 

Ribera J-M, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879–94.

Article  CAS  PubMed  Google Scholar 

Short NJ, Kantarjian H, Jabbour E. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma. 2024;65(10):1405–17.

Article  CAS  PubMed  Google Scholar 

Lv M, Jiang Q, Zhou DB, Hu Y, Liu DH, Wu DP, et al. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. J Hematol Oncol. 2020;13(1):52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters C, Dalle J-H, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: A Multinational, Randomized, noninferiority phase III study. J Clin Oncol. 2021;39(4):295–307.

Article  CAS  PubMed  Google Scholar 

Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of Busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2003;32(6):543–8.

Article  CAS  PubMed  Google Scholar 

Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–96.

Article  PubMed  Google Scholar 

Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–8.

Article  CAS  PubMed  Google Scholar 

Advani AS, Moseley A, O’Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, et al. SWOG 1318: A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia Chromosome-Negative B-Cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878–85.

Article  CAS  PubMed  Google Scholar 

Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, et al. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024;14(1):203.

Article  PubMed  PubMed Central  Google Scholar 

Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-Negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiaretti S, Della Starza I, Santoro A, Spinelli O, Elia L, De Propris MS, et al. Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-Lineage acute lymphoblastic Leukemia. Final results of the phase II Gimema LAL2317 trial. Blood. 2023;142:826.

Article  Google Scholar 

Rijneveld A, Gradowska P, Bellido M, de Weerdt O, Gadisseur A, Deeren D, et al. P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL. HemaSphere. 2022;6:266–7.

Article  Google Scholar